Cystoid macular edema
MONDO:0007935An autosomal dominantly inherited cystoid macular edema manifesting with macular atrophy, strabismus and, sometimes, pericentral retinitis pigmentosa. It is associated with a poor visual prognosis.
Also known as: DCMD, autosomal dominant cystoid macular edema, autosomal dominant cystoid macular oedema, familial macular edema, familial macular oedema, Mddc, cystoid macular dystrophy, macular dystrophy, dominant cystoid
24 clinical trials for this condition and its sub-types, 9 tagged with Cystoid macular edema itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New eye drug could mean fewer shots for Diabetes-Related vision loss
Disease control OngoingThis study tests a new medicine, EYP-1901, given as an eye injection to people with diabetic macular edema (DME), a condition that causes blurry vision in people with diabetes. The goal is to see if EYP-1901 works as well as the standard treatment (aflibercept) but with fewer inj…
Phase 3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New eye drug could cut injection frequency for Diabetes-Related vision loss
Disease control OngoingThis phase 3 trial tests EYP-1901, a new eye injection, against the standard treatment aflibercept for diabetic macular edema (DME), a condition that causes vision loss in people with diabetes. The study will enroll 240 participants and compare how well each drug improves vision …
Phase 3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New app could spot eye disease from your couch
Diagnosis By invitation onlyThis study is testing a smartphone app called NEDS EyeCTester to see if it can help detect active eye disease early in people with conditions like optic nerve or macular disease. About 100 participants will use the app at home, and researchers will compare the results to standard…
Sponsor: Neuro-Eye Diagnostic Systems, LLC • Aim: Diagnosis
Last updated Jun 27, 2026 12:06 UTC
-
Stem cell eye therapy: 5-Year safety watch begins
Knowledge-focused By invitation onlyThis study follows people who received a stem cell treatment for macular degeneration to see if any late side effects appear more than 5 years later. Participants fill out a yearly questionnaire about eye problems, infections, immune disorders, cancer, or other health changes. Th…
Phase 1/2 • Sponsor: Astellas Institute for Regenerative Medicine • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC